HER2 Amplification in p53-Mutated Endometrial Carcinomas
p53-mutated endometrial carcinomas tend to recur and develop distant metastases. Therefore, the detection of new potential therapeutic targets such as HER2 is particularly interesting. In this retrospective study, which considered over 118 endometrial carcinomas, the p53 mutation was detected in 29....
Main Authors: | Ambre Balestra, Denis Larsimont, Jean-Christophe Noël |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/5/1435 |
Similar Items
-
Targeting HER2 expression in cancer: New drugs and new indications
by: Semir Vranić, et al.
Published: (2021-02-01) -
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
by: Binliang Liu, et al.
Published: (2022-07-01) -
Concurrent endometrial intraepithelial carcinoma (EIC) and endometrial hyperplasia
by: Steven Wang, MD, et al.
Published: (2015-03-01) -
TP53 Mutations in Esophageal Squamous Cell Carcinoma
by: Leqi Zhong, et al.
Published: (2023-09-01) -
Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification
by: Ye Hong, et al.
Published: (2021-02-01)